What is the recommended first-line treatment for eosinophilic esophagitis?

Treatment for Eosinophilic Esophagitis

For first-line treatment of eosinophilic esophagitis, you should choose between proton pump inhibitors (PPIs), topical corticosteroids, or elimination diets based on patient preference and clinical context, as all three are equally recommended initial options with strong evidence supporting their efficacy. 1

First-Line Treatment Options

The 2022 British Society of Gastroenterology guidelines provide the most comprehensive and recent framework for EoE management, establishing three equally valid first-line approaches:

Proton Pump Inhibitors (PPIs)

• Dosing: Twice daily for 8-12 weeks before assessing histological response 1
• Evidence: Moderate quality evidence with strong recommendation for inducing histological and clinical remission 1
• Efficacy: Achieves remission in approximately 50% of patients 2
• Advantages: Most accessible, lowest cost, excellent safety profile, effective for long-term maintenance in responders 1
• Mechanism: Anti-inflammatory effects independent of acid suppression 3

Topical Corticosteroids

• Evidence: HIGH quality evidence with strong recommendation—the strongest evidence grade among all treatments 1
• Formulations: Swallowed fluticasone (440-880 mcg twice daily) or budesonide preparations
• Key consideration: Maintenance therapy is required as relapse rates are high after withdrawal (moderate evidence) 1
• Side effects: Esophageal candidiasis is the primary concern 4
• Long-term benefit: Reduces stricture development 1

Elimination Diets

• Evidence: Moderate quality evidence for effectiveness in both adults and children 1
• Approach hierarchy (based on recent paradigm shift):
  • Start with isolated dairy elimination (as effective as more restrictive diets) 5
  • Progress to 2-4 food elimination if dairy alone fails
  • Reserve 6-food elimination diet for refractory cases (higher remission rates but lower compliance and more endoscopies) 1
• Critical requirement: Support from experienced dietitian throughout elimination and reintroduction 1
• Do NOT use: Allergy testing (skin prick, specific IgE, patch testing) to guide dietary choices—strong recommendation against this 1

Treatment Selection Algorithm

Choose based on these patient-specific factors:

1. Start with PPIs if: Patient prefers simplest approach, cost is a concern, or patient has concurrent GERD symptoms
2. Start with topical steroids if: Patient wants therapy with highest quality evidence, can tolerate oral candidiasis risk, and accepts need for long-term maintenance
3. Start with elimination diet if: Patient is motivated for dietary intervention, has access to experienced dietitian, and prefers avoiding medications

Monitoring and Response Assessment

• Endoscopy with biopsy while on treatment is mandatory to assess response, as symptoms do not correlate reliably with histological activity 1
• Histological remission: Defined as <15 eosinophils per 0.3 mm² 1
• Timing: Assess after 8-12 weeks of therapy 1

Second-Line and Adjunctive Therapies

Dupilumab (Biologic Therapy)

• FDA and EMA approved for EoE in patients ≥1 year and ≥15 kg 5, 6
• Use when: PPI-refractory disease or patient has concurrent indication for dupilumab (atopic dermatitis, asthma) 5
• Efficacy: 59-60% histologic remission vs 5-6% placebo at 24 weeks 7
• Limitation: Cost and moderate quality evidence led to conditional recommendation 5

Esophageal Dilation

• Indication: Fibrostenotic disease with persistent dysphagia despite histological remission 1
• Safety: High quality evidence supporting safety with balloon or bougie dilators 1
• Critical point: Must combine with anti-inflammatory therapy (topical steroids preferred) for optimal outcomes 1
• Does NOT treat inflammation: Only addresses mechanical obstruction 8

Important Caveats and Pitfalls

Avoid these common errors:

1. Do NOT combine elimination diets with pharmacological treatment routinely—only consider in drug treatment failure 1
2. Do NOT use: Immunomodulators (azathioprine, 6-mercaptopurine), anti-TNF, anti-integrin therapies—not recommended 1
3. Do NOT use: Montelukast, cromolyn, antihistamines for EoE treatment (moderate evidence against) 1
4. Do NOT stop treatment after initial response: Maintenance therapy is essential as relapse is the rule, not the exception 1
5. Elemental diets: Reserve for refractory cases only due to poor compliance despite high efficacy 1

Maintenance Strategy

• PPIs: Continue at standard doses in responders 1
• Topical steroids: Maintenance required; clinical review should guide dosing 1
• Elimination diets: Continue identified trigger avoidance with dietitian support

If symptoms recur on treatment: Repeat endoscopy with histology immediately 1